PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more
Market Cap & Net Worth: PT Kalbe Farma Tbk (PTKFF)
PT Kalbe Farma Tbk (PINK:PTKFF) has a market capitalization of $3.40 Billion ($3.40 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #6171 globally and #3508 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PT Kalbe Farma Tbk's stock price $0.08 by its total outstanding shares 45315950110 (45.32 Billion).
PT Kalbe Farma Tbk Market Cap History: 2015 to 2025
PT Kalbe Farma Tbk's market capitalization history from 2015 to 2025. Data shows change from $3.29 Billion to $3.40 Billion (-1.44% CAGR).
PT Kalbe Farma Tbk Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PT Kalbe Farma Tbk's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
PT Kalbe Farma Tbk's market cap is 0.00 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
PT Kalbe Farma Tbk's market cap is 0.00 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.29 Billion | $17.89 Trillion | $2.00 Trillion | 0.00x | 0.00x |
| 2016 | $3.70 Billion | $19.37 Trillion | $2.30 Trillion | 0.00x | 0.00x |
| 2017 | $4.93 Billion | $20.18 Trillion | $2.40 Trillion | 0.00x | 0.00x |
| 2018 | $4.19 Billion | $21.07 Trillion | $2.46 Trillion | 0.00x | 0.00x |
| 2019 | $4.62 Billion | $22.63 Trillion | $2.51 Trillion | 0.00x | 0.00x |
| 2020 | $4.74 Billion | $23.11 Trillion | $2.73 Trillion | 0.00x | 0.00x |
| 2021 | $4.89 Billion | $26.26 Trillion | $3.18 Trillion | 0.00x | 0.00x |
| 2022 | $7.56 Billion | $28.93 Trillion | $3.38 Trillion | 0.00x | 0.00x |
| 2023 | $4.64 Billion | $30.45 Trillion | $2.77 Trillion | 0.00x | 0.00x |
| 2024 | $4.31 Billion | $32.63 Trillion | $3.24 Trillion | 0.00x | 0.00x |
Competitor Companies of PTKFF by Market Capitalization
Companies near PT Kalbe Farma Tbk in the global market cap rankings as of March 18, 2026.
Key companies related to PT Kalbe Farma Tbk by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
PT Kalbe Farma Tbk Historical Marketcap From 2015 to 2025
Between 2015 and today, PT Kalbe Farma Tbk's market cap moved from $3.29 Billion to $ 3.40 Billion, with a yearly change of -1.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.40 Billion | -21.03% |
| 2024 | $4.31 Billion | -7.22% |
| 2023 | $4.64 Billion | -38.55% |
| 2022 | $7.56 Billion | +54.44% |
| 2021 | $4.89 Billion | +3.15% |
| 2020 | $4.74 Billion | +2.65% |
| 2019 | $4.62 Billion | +10.27% |
| 2018 | $4.19 Billion | -14.98% |
| 2017 | $4.93 Billion | +33.33% |
| 2016 | $3.70 Billion | +12.55% |
| 2015 | $3.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of PT Kalbe Farma Tbk was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.40 Billion USD |
| MoneyControl | $3.40 Billion USD |
| MarketWatch | $3.40 Billion USD |
| marketcap.company | $3.40 Billion USD |
| Reuters | $3.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.